Tildrakizumab-asmn
RxNorm 2053449

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2053449 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: tildrakizumab-asmn.

The following semantic concepts and normalized strings are associated with this clinical entity:

PIN
Tildrakizumab-asmn
AUI:10328975
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

PINPrescribable

Precise Ingredient (PIN):
Tildrakizumab-asmn
(Atom ID: 10328975)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
tildrakizumab-asmn
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2053449
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
10328975
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PIN
Precise Ingredient (A specified form of the ingredient that may or may not be clinically active. Most precise ingredients are salt or isomer forms.)
Source Code
2053449
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Tildrakizumab-asmn injection


Tildrakizumab-asmn injection is used to treat moderate to severe plaque psoriasis (a skin disease in which red, scaly patches form on some areas of the body) in people whose psoriasis is too severe to be treated by topical medications alone. Tildrakizumab-asmn injection is in a class of medications called monoclonal antibodies. It works by stopping the action of certain natural substances in the body that cause the symptoms of psoriasis.
[Learn More]


* Please review the disclaimer below.